Posted by Michael Wonder on 22 Sep 2024
Wegovy recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
19 September 2024 - Novo Nordisk today announced that the EMA's CHMP has adopted a positive opinion for an update of the Wegovy (semaglutide 2.4 mg) label in the European Union.
The label update incorporates data showing that Wegovy, when added to standard of care, can reduce heart failure related symptoms and improve physical limitations and exercise function in people with obesity-related HFpEF, with or without type 2 diabetes.
